Literature DB >> 10627455

Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro.

N S Weich1, M Fitzgerald, A Wang, J Calvetti, J Yetz-Aldape, S Neben, K J Turner.   

Abstract

The authors studied the role that interleukin (IL)-11 plays during the early stages of megakaryocyte (MK) development by investigating its in vitro effects on cell subpopulations enriched for bone marrow primitive progenitor cells and early and late committed progenitor cells. Progenitor subpopulations were isolated from bone marrow of normal or 5-fluorouracil (5FU)-treated mice and separated by sorting based on the surface antigens Sca-1, c-kit, and CD34. Functional analysis of the cell subpopulations, 5FU Lin(-)Sca-1(+)c-kit(+) or normal bone marrow (NBM) Lin(-)Sca-1(+)c-kit(+)CD34(-)cells, indicated that exposure of these cells to recombinant human (rh)IL-11 in combination with steel factor (SF) stimulates the formation of colonies in methylcellulose and their proliferation in single cell-containing liquid cultures. Kinetic studies of MK progenitor generation, in response to SF and rhIL-11, demonstrated that a significant number of the progenitors produced are committed to the MK lineage. RhIL-11 also synergized with both SF and IL-3 to stimulate MK colony growth from NBM Lin(-)Sca-1(+)c-kit(+) cells (early progenitors) and NBM Lin(-)Sca-1(-)c-kit(+) cells (committed late progenitors). In the presence of IL-3, NBM, Lin(-)Sca-1(-)c-kit(+) cells responded more strongly to rhIL-11 than SF. Consistent with these results is the observation that IL-11 receptor alpha chain mRNA is present in all the progenitor cells from which the MKs are derived. This cell culture and RNA analysis suggest that murine bone marrow primitive progenitor cells and early and late progenitor cells are direct targets of rhIL-11 and that rhIL-11 has the potential to promote megakaryocyte development at several very early stages. (Blood, 2000;95:503-509) (Blood. 2000;95:503-509)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627455

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  The role of platelet factor 4 in radiation-induced thrombocytopenia.

Authors:  Michele P Lambert; Liqing Xiao; Yvonne Nguyen; M Anna Kowalska; Mortimer Poncz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-08-01       Impact factor: 7.038

2.  Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes.

Authors:  Michele P Lambert; Yuhuan Wang; Khalil H Bdeir; Yvonne Nguyen; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

3.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

4.  Transcriptomic analysis of early B-cell development in the chicken embryo.

Authors:  Nikhil K Nuthalapati; Jeffrey D Evans; Robert L Taylor; Scott L Branton; Bindu Nanduri; Gregory T Pharr
Journal:  Poult Sci       Date:  2019-11-01       Impact factor: 3.352

5.  Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.

Authors:  Bijender Kumar; Vahid Afshar-Kharghan; Mayela Mendt; Robert Sackstein; Mark R Tanner; Uday Popat; Jeremy Ramdial; May Daher; Juan Jimenez; Rafet Basar; Luciana Melo Garcia; Mayra Shanley; Mecit Kaplan; Xinhai Wan; Vandana Nandivada; Francia Reyes Silva; Vernikka Woods; April Gilbert; Ricardo Gonzalez-Delgado; Sunil Acharya; Paul Lin; Hind Rafei; Pinaki Prosad Banerjee; Elizabeth J Shpall
Journal:  Front Immunol       Date:  2022-09-20       Impact factor: 8.786

6.  Designer cytokine hyper interleukin 11 (H11) is a megakaryopoietic factor.

Authors:  Hanna Dams-Kozlowska; Eliza Kwiatkowska-Borowczyk; Katarzyna Gryska; Andrzej Mackiewicz
Journal:  Int J Med Sci       Date:  2013-07-09       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.